Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

DARK SECRETS: Astrazeneca calms pricing jitters says us deal hit absorbable - The Real Truth

Shanghai,china-feb.12th,2023:,Astrazeneca,Company,Office,Building,And,Brand,Logo.

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion, driven by double-digit growth in oncology, CVRM, and biopharmaceuticals.

The company’s adjusted EPADS reached $1.19, beating the consensus of $1.14. The adjusted EPS was $2.38 (1 ADR = 2 Common Shares).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.